Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
It is also listed on the PBS for patients who fulfill the following key clinical criteria: an eGFR of 25 mL/min/1.73 m 2 or greater an ACR of 22.6 mg/mmol or greater must be on a stable dose of either an ACE inhibitor or ARB must not have established heart failure with reduced ejection fraction must be on an SGLT-2 inhibitor unless medically contraindicated or intolerant (please refer to the full PBS clinical criteria at: Combination therapy Some evidence suggests that combination therapy with SGLT-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and CKD reduces the risk of CV events and the mineralocorticoid receptor antagonist-associated risk of hyperkalaemia without a significant interaction between the two drugs
Risks to Watch : Dehydration, hypoglycemia (when combined with insulin), and interactions with other medications
Your clinician should help set goals based on your health and starting point
10.1185/030079902125000200 41 DeFronzoR
